Utilization of statins, an HMG-CoA reductase inhibitors, in Ambon District Hospital, Maluku: a retrospective study

Simatupang, Abraham and Huningkor, Yusuf and Gasperz, Westi C and Nindatu, Maria and Noya, Farah and Sanaky, Marliyati and Hutagalung, Inggrid and Yolanda, Denny and Kailola, Natalie (2018) Utilization of statins, an HMG-CoA reductase inhibitors, in Ambon District Hospital, Maluku: a retrospective study. Journal of the Medical Sciences, 50 (2). pp. 209-215. ISSN 0126 1312

Preview	Text 321.Abraham Simatupang 2018.pdf Download (306kB) | Preview
Preview	Text (Reviewer) Utilization.pdf Download (722kB) | Preview
Preview	Text (Hasil Cek Turnitin) Utilization of statins, an HMG-CoA reductase inhibitors, in Ambon District Hospital, Maluku a retrospective study.pdf Download (1MB) | Preview

Abstract

Non-infectious diseases, including hypercholesterolemia, are now ranked top 10 in Indonesia. Statins are inhibitors of HMG-CoA reductase, an enzyme for biosynthesis of cholesterol in the liver. Statins have been proven to reduce the risk of death due to CHD and mortality from various reasons. The objective of the study is to know the utilization of statins in peripheral area of Indonesia. This retrospective study on utilization of statins prescribed for hypercholesterolemia was taken from medical record year of 2014-2015 of a District Hospital – Dr. Haulussy, Ambon, and Maluku. We collected demographic data, pre- and treated concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG), types and dosages of statins or other lipid-lowering medications given. Student t-test using was performed to check statistical differences for all cholesterol and TG differences prior to therapy versus during treatment. Eighty three respondents consisted of 26 men (31.3%) and 57 women (68.7%) with mean age 60 ± 11 years old. The pre-treatment/ post-treatment values (mg/dL) of TC: 245.22 ± 51.40/224.97 ± 98.79 (p=0.004); LDL-C: 166.07 ± 45.36/146.00 ± 41.07; HDL-C: 54.52 ± 37.95/43.00 ± 0.00; and TG: 177.36 ± 103.25/121.00 ± 52.87, respectively. Seventy-nine patients (95.2%) were treated with statins. The dosage given were 10 mg (n=19, 22.9%), 20 mg (n= 63, 75.9%), and 40 mg (n=1, 1.2%). Twenty-eight patients (33.7%) had no posttreatment data of cholesterol, and 31 out of 55 patients (56%) were responders. All cholesterol levels were decreased, but responder rate was only 56%. Therefore, dosage adjustment and prerequisite cholesterol level during and post-treatment measurement should be made regularly. Keywords: Statins, drug utilization, hypercholesterolemia, HMG-CoA reductase inhibitor

Actions (login required)

View Item